MedTrace Logo

Study of Perifosine + Capecitabine for Colon Cancer Patients

NCT01048580 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-06-28

No results posted yet for this study

Summary

This is a Phase I study of Perifosine + Capecitabine for patients with advanced colon cancer.

Conditions

Interventions

DRUG

Perifosine

Perifosine 50 mg orally once a day (Days 1-21)

DRUG

Capecitabine

Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)

Sponsors & Collaborators

  • SCRI Development Innovations, LLC

    collaborator OTHER

  • AEterna Zentaris

    lead INDUSTRY

Principal Investigators

  • Johanna Bendell,, MD · SCRI Development Innovations, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-05-31
Completion
2011-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01048580 on ClinicalTrials.gov